Management of painful diabetic neuropathy

Mitra Tavakoli, Rayaz Malik

Research output: Contribution to journalReview article

19 Citations (Scopus)

Abstract

The commonest cause of peripheral neuropathy is diabetes and pain occurs in ∼ 30% of diabetic patients with neuropathy. It is extremely distressing for the patient and poses significant difficulties in management, as no treatment to date provides total relief and the side effects of therapy limit dose titration. Understanding the pathogenesis of diabetic neuropathy may lead to the development of new treatments for preventing nerve damage. Furthermore, a better understanding of the mechanisms that modulate pain may lead to more effective relief of painful symptoms. This review provides an update on the assessment and treatment of painful diabetic neuropathy.

Original languageEnglish
Pages (from-to)2969-2978
Number of pages10
JournalExpert Opinion on Pharmacotherapy
Volume9
Issue number17
DOIs
Publication statusPublished - Dec 2008
Externally publishedYes

Fingerprint

Diabetic Neuropathies
Pain
Peripheral Nervous System Diseases
Therapeutics

Keywords

  • Diabetic neuropathy
  • Pathogenetic treatment
  • Symptomatic therapy

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Pharmacology

Cite this

Management of painful diabetic neuropathy. / Tavakoli, Mitra; Malik, Rayaz.

In: Expert Opinion on Pharmacotherapy, Vol. 9, No. 17, 12.2008, p. 2969-2978.

Research output: Contribution to journalReview article

Tavakoli, Mitra ; Malik, Rayaz. / Management of painful diabetic neuropathy. In: Expert Opinion on Pharmacotherapy. 2008 ; Vol. 9, No. 17. pp. 2969-2978.
@article{b9995b2e351a4809ae24b2639a6f4b64,
title = "Management of painful diabetic neuropathy",
abstract = "The commonest cause of peripheral neuropathy is diabetes and pain occurs in ∼ 30{\%} of diabetic patients with neuropathy. It is extremely distressing for the patient and poses significant difficulties in management, as no treatment to date provides total relief and the side effects of therapy limit dose titration. Understanding the pathogenesis of diabetic neuropathy may lead to the development of new treatments for preventing nerve damage. Furthermore, a better understanding of the mechanisms that modulate pain may lead to more effective relief of painful symptoms. This review provides an update on the assessment and treatment of painful diabetic neuropathy.",
keywords = "Diabetic neuropathy, Pathogenetic treatment, Symptomatic therapy",
author = "Mitra Tavakoli and Rayaz Malik",
year = "2008",
month = "12",
doi = "10.1517/14656560802498149",
language = "English",
volume = "9",
pages = "2969--2978",
journal = "Expert Opinion on Pharmacotherapy",
issn = "1465-6566",
publisher = "Informa Healthcare",
number = "17",

}

TY - JOUR

T1 - Management of painful diabetic neuropathy

AU - Tavakoli, Mitra

AU - Malik, Rayaz

PY - 2008/12

Y1 - 2008/12

N2 - The commonest cause of peripheral neuropathy is diabetes and pain occurs in ∼ 30% of diabetic patients with neuropathy. It is extremely distressing for the patient and poses significant difficulties in management, as no treatment to date provides total relief and the side effects of therapy limit dose titration. Understanding the pathogenesis of diabetic neuropathy may lead to the development of new treatments for preventing nerve damage. Furthermore, a better understanding of the mechanisms that modulate pain may lead to more effective relief of painful symptoms. This review provides an update on the assessment and treatment of painful diabetic neuropathy.

AB - The commonest cause of peripheral neuropathy is diabetes and pain occurs in ∼ 30% of diabetic patients with neuropathy. It is extremely distressing for the patient and poses significant difficulties in management, as no treatment to date provides total relief and the side effects of therapy limit dose titration. Understanding the pathogenesis of diabetic neuropathy may lead to the development of new treatments for preventing nerve damage. Furthermore, a better understanding of the mechanisms that modulate pain may lead to more effective relief of painful symptoms. This review provides an update on the assessment and treatment of painful diabetic neuropathy.

KW - Diabetic neuropathy

KW - Pathogenetic treatment

KW - Symptomatic therapy

UR - http://www.scopus.com/inward/record.url?scp=57549107863&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=57549107863&partnerID=8YFLogxK

U2 - 10.1517/14656560802498149

DO - 10.1517/14656560802498149

M3 - Review article

C2 - 19006473

AN - SCOPUS:57549107863

VL - 9

SP - 2969

EP - 2978

JO - Expert Opinion on Pharmacotherapy

JF - Expert Opinion on Pharmacotherapy

SN - 1465-6566

IS - 17

ER -